NO894942L - Fremgangsmaate for behandling av autoimmune sykdommer. - Google Patents

Fremgangsmaate for behandling av autoimmune sykdommer.

Info

Publication number
NO894942L
NO894942L NO89894942A NO894942A NO894942L NO 894942 L NO894942 L NO 894942L NO 89894942 A NO89894942 A NO 89894942A NO 894942 A NO894942 A NO 894942A NO 894942 L NO894942 L NO 894942L
Authority
NO
Norway
Prior art keywords
procedure
immune diseases
naltrexone
treating
nalmefene
Prior art date
Application number
NO89894942A
Other languages
English (en)
Norwegian (no)
Other versions
NO894942D0 (no
Inventor
Fred P Sherman
David C Atkinson
Original Assignee
Baker Cummins Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Cummins Pharma filed Critical Baker Cummins Pharma
Publication of NO894942D0 publication Critical patent/NO894942D0/no
Publication of NO894942L publication Critical patent/NO894942L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO89894942A 1988-12-15 1989-12-08 Fremgangsmaate for behandling av autoimmune sykdommer. NO894942L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/284,615 US4857533A (en) 1988-12-15 1988-12-15 Method of treatment for autoimmune diseases

Publications (2)

Publication Number Publication Date
NO894942D0 NO894942D0 (no) 1989-12-08
NO894942L true NO894942L (no) 1990-06-18

Family

ID=23090868

Family Applications (1)

Application Number Title Priority Date Filing Date
NO89894942A NO894942L (no) 1988-12-15 1989-12-08 Fremgangsmaate for behandling av autoimmune sykdommer.

Country Status (11)

Country Link
US (1) US4857533A (ja)
EP (1) EP0373744B1 (ja)
JP (1) JPH07555B2 (ja)
AT (1) ATE107508T1 (ja)
AU (1) AU617494B2 (ja)
CA (1) CA1333569C (ja)
DE (1) DE68916387T2 (ja)
DK (1) DK630789A (ja)
IL (1) IL92269A (ja)
NO (1) NO894942L (ja)
ZA (1) ZA899028B (ja)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013739A (en) * 1986-10-07 1991-05-07 Bernard Bihari Method of treating chronic fatigue syndrome using an opiate receptor antagonist
US4877791A (en) * 1988-11-01 1989-10-31 Baker Cummins Pharmaceuticals, Inc. Method of treatment for interestitial cystitis
US5348729A (en) * 1988-11-30 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
JP2906654B2 (ja) * 1989-11-28 1999-06-21 東レ株式会社 免疫抑制剤及びその製造方法
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
US5376662A (en) * 1993-12-08 1994-12-27 Ockert; David M. Method of attenuating nerve injury induced pain
SE9304236D0 (sv) * 1993-12-22 1993-12-22 Astra Ab New use
US5878750A (en) * 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US6203813B1 (en) 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7285544B2 (en) * 2003-11-18 2007-10-23 Bernstein Eric F Use of nitroxides in treating skin disease
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
GB0509052D0 (en) * 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US20070259939A1 (en) * 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
CL2008000905A1 (es) 2007-03-29 2008-08-22 Progenics Pharm Inc Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena.
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
SI2565195T1 (sl) 2007-03-29 2015-09-30 Wyeth Llc Periferalni opioidni receptorji in antagonisti in njih uporaba
EP2240489A1 (en) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
SI2379066T1 (sl) * 2008-09-16 2014-08-29 Imuneks Farma Ilac Sanayi Ve Ticaret A.S. Uporaba opioidnih antagonistov za pripravo zdravila za zdravljenje degenerativnih bolezni retine
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
TR201002473A2 (tr) 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
US20120252831A1 (en) * 2011-03-31 2012-10-04 Mustafa Nevzat Ilac Sanayii A.S. Compositions of opioid antagonists and methods for treating scleroderma therewith
US9757372B2 (en) * 2015-03-25 2017-09-12 Taiwanj Pharmaceuticals Co., Ltd. Toll-like receptor 4 antagonists and use in autoimmune liver diseases
PT4293009T (pt) 2015-12-22 2025-09-08 Zogenix International Ltd Composições de fenfluramina e métodos de preparação das mesmas
EP3939570A1 (en) * 2016-02-18 2022-01-19 Immune Therapeutics, Inc. Naltrexone for treating or preventing autoimmune and inflammatory diseases
WO2021055448A1 (en) 2019-09-16 2021-03-25 Figene, Llc Treatment of disc degenerative disease and stimulation of proteoglycan synthesis by fibroblast conditioned media and formulations thereof
WO2022191615A1 (ko) * 2021-03-09 2022-09-15 (주)인벤티지랩 저용량 날트렉손을 함유하는 자가면역질환 예방 또는 치료용 서방성 제제 및 이를 이용한 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51145B1 (en) * 1980-03-07 1986-10-15 Efamol Ltd Pharmaceutical and dietary compositions
HU196376B (en) * 1985-05-23 1988-11-28 Sandoz Ag Process for preparing morphinane derivatives and pharmaceutical compositions containing such compounds
FR2609632B1 (fr) * 1987-01-21 1991-03-29 Shelly Marc Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage
US4880813A (en) * 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis
DK160590C (da) * 1988-09-12 1991-09-16 Fls Airloq As Fremgangsmaade til detektering af en gasart ved hjaelp af fotoakustisk spektroskopi
US4877791A (en) * 1988-11-01 1989-10-31 Baker Cummins Pharmaceuticals, Inc. Method of treatment for interestitial cystitis
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases

Also Published As

Publication number Publication date
JPH02184627A (ja) 1990-07-19
IL92269A0 (en) 1990-07-26
AU3827989A (en) 1990-06-21
JPH07555B2 (ja) 1995-01-11
NO894942D0 (no) 1989-12-08
DK630789D0 (da) 1989-12-13
EP0373744A3 (en) 1991-09-18
IL92269A (en) 1994-04-12
EP0373744A2 (en) 1990-06-20
AU617494B2 (en) 1991-11-28
CA1333569C (en) 1994-12-20
DK630789A (da) 1990-06-16
ZA899028B (en) 1990-08-29
DE68916387T2 (de) 1994-10-13
DE68916387D1 (de) 1994-07-28
US4857533A (en) 1989-08-15
ATE107508T1 (de) 1994-07-15
EP0373744B1 (en) 1994-06-22

Similar Documents

Publication Publication Date Title
NO894942L (no) Fremgangsmaate for behandling av autoimmune sykdommer.
EP0377272A3 (en) Use of nalmefene or naltrexone in the manufacture of a medicament for the treatment of inflammation in an arthritic disease or associated inflammatory diseases
NO894295D0 (no) Fremgangsmaate for behandling av interstitiell cystitt.
IL99699A0 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
EP0359783A4 (en) TREATING AUTOIMMUNE DISEASES BY ORAL ADMINISTRATION OF AUTOANTIGENS.
NL970006I1 (nl) Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson.
ES2137948T3 (es) Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina.
PT627933E (pt) Supressao "bystander" de doencas autoimunes
NO173726C (no) Fremgangsmaate for fremstilling av et oralt terapeutisk system for administrering av karbamazpin
ATE67677T1 (de) Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten.
DK0459666T3 (da) Lægemidler mod impotens
EA199600029A2 (ru) Оральная композиция, содержащая s(+)-этодолак, способ ее получения
GR1000419B (el) Μορφη δοσολογιας για χορηγηση ανταγωνιστη του ασβεστιου.
DE69113921D1 (de) Verwendung eines reinen Opiatantagonisten, z.B. Nalmefen, Naltrexon, Naloxon oder Diprenorphin, zur Behandlung von Mastzell-Erkrankungen.
IT9086204A0 (it) Metodo per la cura dell'impotenza erettiva maschile
GR900300082T1 (en) Use of dapiprazole for the manufacture of a pharmaceutical composition inhibiting the development of tolerance in the analgesic treatment with morphine
ATE2272T1 (de) 9,10-dihydro-4h-benzo(4,5)cyclohepta(1,2b)thiophen-4,9-imine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
OA09790A (en) "Paromomycin or its derivatives or salts thereof for parenteral treatment of human parasitic diseases".
IT8919216A0 (it) Dispositivo per la cura chirurgica dell'astigmatismo.